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Abstract
Background: Somatic mutations of mitochondrial DNA (mtDNA) are common in many human
cancers. We have described an oligonucleotide microarray ("MitoChip") for rapid sequencing of
the entire mitochondrial genome (Zhou et al, J Mol Diagn 2006), facilitating the analysis of mtDNA
mutations in preneoplastic lesions. We examined 14 precancerous lesions, including seven Barrett
esophagus biopsies, with or without associated dysplasia; four colorectal adenomas; and three
inflammatory colitis-associated dysplasia specimens. In all cases, matched normal tissues from the
corresponding site were obtained as germline control. MitoChip analysis was performed on DNA
obtained from cryostat-embedded specimens.
Results: A total of 513,639 bases of mtDNA were sequenced in the 14 samples, with 490,224
bases (95.4%) bases assigned by the automated genotyping software. All preneoplastic lesions
examined demonstrated at least one somatic mtDNA sequence alteration. Of the 100 somatic
mtDNA alterations observed in the 14 cases, 27 were non-synonymous coding region mutations
(i.e., resulting in an amino acid change), 36 were synonymous, and 37 involved non-coding mtDNA.
Overall, somatic alterations most commonly involved the COI, ND4 and ND5 genes. Notably,
somatic mtDNA alterations were observed in preneoplastic lesions of the gastrointestinal tract
even in the absence of histopathologic evidence of dysplasia, suggesting that the mitochondrial
genome is susceptible at the earliest stages of multistep cancer progression.
Conclusion:  Our findings further substantiate the rationale for exploring the mitochondrial
genome as a biomarker for the early diagnosis of cancer, and confirm the utility of a high-
throughput array-based platform for this purpose from a clinical applicability standpoint.
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Background
Somatic mutations of the mitochondrial DNA (mtDNA)
are common in many human cancers, likely a reflection of
altered DNA repair mechanisms and predisposition of
mtDNA to free radical damage [1-3]. Although the func-
tional significance of these mutations has been debated
vis-à-vis their "cause and effect" relationship in cancer
cells, there is little doubt that mtDNA mutations can serve
an important role as a biomarker for human cancers [4-6].
Nevertheless, despite the frequency and widespread
nature of mtDNA alterations in human cancers, the ability
to use this property for biomarker development has been
stymied due to the absence of high-throughput platforms
for mutation detection. Unlike many nuclear genes that
demonstrate mutational hotspots, mtDNA mutations can
occur anywhere along the 16.5 kB bases of its genome [7-
11]. Therefore, assays for mutational analysis of mtDNA
in cancers, unlike those meant to detect specific metabolic
disease-associated alterations, need to be "global". Even
though certain focused assays such polymorphic repeat
analysis of the so-called "D310 poly-C" tract in the non-
coding D-loop have been designed [12-14], these, not
unexpectedly, have lower sensitivities than what would be
expected from complete sequencing of the mitochondrial
genome. Moreover, mtDNA mutations in cancer are often
heteroplasmic, and therefore, an added caveat over
throughput and scale of the assay is its sensitivity for
detecting aberrant clones within heterogenous templates
[4].
In order to surmount these challenges of mtDNA muta-
tional analysis in human cancers, we developed the first
oligonucleotide-based sequencing microarray (MitoChip
version 1.0) in 2004, which is capable of sequencing the
mtDNA coding region on a single platform [15]. We and
others have previously demonstrated the ability of this
array for high throughput sequencing of the mtDNA
genome, and confirmed the sensitivity and accuracy of
this platform over conventional sequencing technologies
[4,15-17]. More recently, we have validated a second gen-
eration oligonucleotide microarray (MitoChip version
2.0), that preserves many of the features of the earlier
array, but has the added advantage of being able to
sequence the entire 16,569 bases of mtDNA, including
both the coding and non-coding regions [18]. The second
generation arrays demonstrate >99.99% reproducibility
of base calls in replicate experiments, and harbor greater
sensitivity of detecting heteroplasmic mutations than
either the first-generation MitoChip or conventional dye-
terminator sequencing.
In this study, we utilize the MitoChip v2.0 arrays for
detecting somatic mtDNA alterations in preneoplastic
lesions of the gastrointestinal tract (Barrett esophagus,
colorectal adenomas, and colitis-associated dysplasia). To
our knowledge, this is the first report of complete mito-
chondrial genome sequencing in preneoplastic lesions of
the GI tract, and provides unequivocal, albeit preliminary,
evidence that mtDNA alterations are a frequent and early
event in the multistep progression model of gastrointesti-
nal neoplasia. These findings lay the groundwork for
exploring mtDNA mutations as a biomarker for early
detection of cancer utilizing high-throughput, array-based
sequencing technologies.
Materials and methods
Tissue samples for mtDNA analysis
The studies performed were approved by the Institutional
Review Boards of the Johns Hopkins University and
Howard University School of Medicine. Fourteen individ-
ual preneoplastic lesions with matched normal samples,
totaling 31 specimens overall, were accrued as follows
(Table 1): seven Barrett esophagus cases were obtained
from upper GI endoscopic biopsies, each from an individ-
ual patient. In all seven cases, normal squamous mucosa
was obtained as a source of matched germline control.
Cryosections were prepared from the snap-frozen biopsies
to confirm histology of the lesions, performed by two
trained gastrointestinal pathologists (A.M. and E.A.M.); of
the cases utilized, two biopsies demonstrated Barrett
mucosa without concomitant dysplasia, four exhibited
low-grade dysplasia, and one demonstrated high-grade
dysplasia, diagnosed using previously described histo-
logic criteria for dysplasia in Barrett esophagus [19]. On
the same lines, four colorectal adenomas were obtained
from four individual patients, with biopsies of non-ade-
nomatous colonic epithelium utilized as a source of germ-
line control. Cryosections were prepared from snap-
frozen excess adenoma tissue after samples had been sub-
mitted for routine histopathologic diagnosis, in order to
confirm the diagnosis and integrity of tissue being sub-
mitted for sequencing array analysis. Of the four adenoma
specimens, three were tubular adenomas and one was a
sessile serrated adenoma (SSA) from the recto-sigmoid
region [20,21]; none demonstrated evidence of invasive
adenocarcinoma. Snap-frozen samples of colitis-associ-
ated dysplasia were obtained from three patients undergo-
ing colectomy for long-standing idiopathic bowel disease
(IBD) with concomitant dysplasia. Nine samples were
obtained from the three colectomy specimens, and cryo-
sections prepared in order to confirm the histopathologic
diagnosis; three patients harbored dysplasia associated
lesion or mass (DALM), a precursor of colitis-associated
colorectal cancer [22,23]. Two patients had frank malig-
nancies that were topographically distinct from the DALM
lesions, and these were also submitted for array analysis.
We were unable to obtain histologically unremarkable
colonic mucosa in these patients, and therefore areas of
inactive colitis was used as germline control, with the
implicit understanding that these may potentially harborMolecular Cancer 2006, 5:73 http://www.molecular-cancer.com/content/5/1/73
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mtDNA alterations distinct from true normal colonic
mucosa; an area of active colitis was also examined in one
patient. DNA was obtained from cryosections prepared
from the 31 samples as described; no additional enrich-
ment for a mitochondrial fraction is required for Mito-
Chip analysis.
PCR amplification, fragmentation, labeling and array 
hybridization
Samples were prepared for MitoChip analysis as we have
previously described [18]. Briefly, long-range PCR was
performed using three PCR primer sets that can amplify
the entire mtDNA, using 100 ng of input DNA for each
reaction. The cycling conditions for all reactions were: (1)
95°C for 2 min; (2) 95°C for 15 seconds; (3) 68°C for 7
min; (4) repeat step 2 for 29 times; (5) final extension for
12 min. As a control for PCR amplification and subse-
quent hybridization, a 7.5 kb plasmid DNA (Tag IQ-EX
template) was amplified concomitantly with the test sam-
ples, using forward and reverse primers included in the
CustomSeq™ kit (Affymetrix, Inc.). The procedures for
sample pooling, DNA fragmentation and labeling are
identical for both first and second-generation MitoChip
assays, and a detailed protocol has been previously
described [15,18]. Pre-hybridization, hybridization,
washing, and scanning of the MitoChip were performed
as described in the Affymetrix CustomSeq™ Resequencing
protocol.
Automated batch analysis of MitoChip data
The analysis of microarray data was performed using RA
Tools, a modified version of the previously described
adaptive background genotype-calling scheme (ABACUS)
[24]; the open source software is available at [25]. Briefly,
RA Tools uses an objective statistical framework to assign
each genotype call a "quality score", which is the differ-
ence between the log (base 10) likelihood of the best fit-
ting and the second best fitting statistical model for
assigning a genotype at any position on the sequencing
array. The total quality score threshold (totThresh) is the
quality score that a given base has to exceed in order to be
called. Increasing this value requires increased support for
basecalls, and as a consequence, fewer bases are called.
Bases that fail to reach this thresold are called "N." The
optimum total threshold quality score was determined
empirically to be 12, which yields the highest base call
rate with the lowest discrepancy between genotypes for
replicate samples, as previously described [18]. The
Revised Cambridge Reference Sequence (RCRS) was used
as the reference against which germline and lesional tis-
sues were compared, and the MitoAnalyzer software [26]
was used to query the impact on translated protein, if any,
of mtDNA alterations.
Microsatellite instability and identity analysis
Microsatellite instability analysis was performed on the
one sessile serrated adenoma (SSA) specimen and its
matched control tissue using the MSI Analysis System
(Promega). In order to exclude the possibility of a sample
mismatch, identity testing was performed on the SSA and
its matched normal sample using the AmpF STR Identi-
filer PCR Amplification kit (Applied Biosystems).
Results
A total of 513,639 base pairs of mtDNA were sequenced
across the 31 samples, at 16,569 bases per sample. Using
the above described base calling criteria, 490,224 base
pairs (95.4%) were assigned. The range of base calls was
88.2–96.9%, with a median call rate of 95.9% (Table 2).
As detailed in Additional file 1, at least one somatic alter-
ation in the mtDNA was identified in all 14 specimens of
preneoplasia, with a range of 1–35 sequence variations
compared to matched germline controls [see Additional
file 1]. When stratified by their position in the mitochon-
drial genome, the sequence alterations were widely dis-
tributed, reiterating the need for a "global" sequencing
Table 1: Preneoplastic lesions of the GI tract used for mitochondrial DNA analysis
Case Histology of Preneoplastic Lesion Matched Normal
1 Barrett esophagus, negative for dysplasia Yes; squamous mucosa
2 Barrett esophagus, negative for dysplasia Yes; squamous mucosa
3 Barrett esophagus with low grade dysplasia Yes; squamous mucosa
4 Barrett esophagus with low grade dysplasia Yes; squamous mucosa
5 Barrett esophagus with low grade dysplasia Yes; squamous mucosa
6 Barrett esophagus with low grade dysplasia Yes; squamous mucosa
7 Barrett esophagus with high grade dysplasia Yes; squamous mucosa
8 Tubular adenoma Yes; colonic mucosa
9 Tubular adenoma Yes; colonic mucosa
10 Tubular adenoma Yes; colonic mucosa
11 Sessile serrated adenoma Yes; colonic mucosa
12 Dysplasia associated lesion or mass (DALM) No; inactive and active colitis
13 Dysplasia associated lesion or mass (DALM) No; inactive colitis
14 Dysplasia associated lesion or mass (DALM) No; inactive colitisMolecular Cancer 2006, 5:73 http://www.molecular-cancer.com/content/5/1/73
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strategy rather than focused mutational analysis. Of the
100 somatic sequence alterations, 27 (27%) were non-
synonymous, i.e. resulting in an amino acid change, 36
(36%) were synonymous, and 37 (37%) involved the
non-coding displacement D-loop, t-RNA and 12/16S RNA
genes. As seen in Figure 1, the COI, ND4 and ND5 genes
were the ones most commonly affected by sequence alter-
ations, once the non-coding region was excluded. This
distribution is comparable to the mutational spectrum
reported in previous studies using cancer specimens [4,8-
10].
When the individual samples and associated sequence
alterations were studied, several notable trends emerged.
The majority of sequence alterations were heteroplasmic
in nature, which could either reflect emergence of an aber-
rant clone with intracellular heteroplasmy, or distinct
homoplasmic cellular populations within the lesion, or
both. Since samples were not microdissected and almost
certainly contained non-lesional cell types (stroma,
endothelium, etc.), it is likely that we are over-estimating
the frequency of heteroplasmy. In the seven Barrett
esophagus samples, we found no significant differences in
the overall frequency of alterations between samples with
no dysplasia and those with dysplastic epithelium; never-
theless, there was a trend towards higher rate of non-syn-
onymous mutations in samples with dysplasia (9/23 or
39%) versus those without dysplasia (2/15 or 13%). With
the exception of a recurrent sequence alteration in 16S
RNA at nucleotide position 1949 in two Barrett samples,
other somatic variations were unique to each specimen.
Several recurrent (i.e., in more than one specimen)
sequence alterations were seen in the four adenoma sam-
ples [see Additional file 1], but one non-synonymous
mutation in particular, Thr415Ala in the COI gene was
observed in 3 of 4 adenomas, suggesting a putative path-
ogenic role. Of the four colorectal polyps, one specimen
(a recto-sigmoid sessile serrated adenoma [SSA], Figure 2)
had 35 mtDNA alterations, including six non-synony-
mous mutations. Notably, all but one of the sequence
alterations was a transition. In order to exclude the possi-
bility of sample mismatch, we performed identity testing
on DNA from the normal colonic mucosa and the SSA,
and this analysis confirmed a perfect match. Nuclear mic-
rosatellite instability (MSI) was excluded by analysis of
matched normal and adenoma DNA; i.e., per the
Bethesda criteria [27], the SSA was "microsatellite stable"
(data not shown). Three of 3 colitis-associated dysplasia
samples demonstrated at least one somatic alteration,
with the associated cancers demonstrating additional
mtDNA changes. Of note, the two associated carcinomas
Distribution of somatic mtDNA alterations in preneoplastic lesions of the gastrointestinal tract by their location in the mito- chondrial genome Figure 1
Distribution of somatic mtDNA alterations in preneoplastic lesions of the gastrointestinal tract by their location in the mito-
chondrial genome.Molecular Cancer 2006, 5:73 http://www.molecular-cancer.com/content/5/1/73
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shared a subset of genetic alterations with the synchro-
nous, albeit topographically distinct, dysplastic lesions,
arguing for a potential field defect shared across the
colonic epithelium. However, no shared alterations were
seen across the three IBD cases.
Discussion
Array-based analysis of the entire mitochondrial genome
demonstrates that precursor lesions of epithelial cancers
harbor somatic mtDNA alterations much like their inva-
sive counterparts. Limited sequencing of mtDNA using
conventional techniques has previously identified
somatic alterations in precursor lesions. For example, a
poly-C tract known as D310 in the non-coding D-loop is
commonly mutated in many cancers, and was recently
been shown to be mutated in precursor lesions of head
and neck cancer, esophageal adenocarcinoma, and gall-
bladder adenocarcinoma [13,28,29]. The current study
provides, for the first time, an insight into the prevalence
and distribution of mtDNA alterations in precursor
lesions on a "global" scale. The rationale for preferential
sequencing of the non-coding region of mtDNA has been
the assumption that this portion of the mitochondrial
genome is particularly susceptible to the rigors of DNA
damage encountered in metabolically active cancer cells
[30]. However, our studies and those of others continue to
provide evidence that the coding region is at least equally
susceptible to DNA alterations in cancer [4,7]. In as many
as 7 of 14 (50%) preneoplastic samples, we detected
somatic alterations restricted to the coding region of
mtDNA, while two additional cases had only single non-
coding D-loop changes in addition to coding region alter-
ations [see Additional file 1]. In addition, the relatively
low level of recurrent mutations at any given nucleotide
position also suggests that selective sequencing of so-
called "hot spots" may not provide the same yield as
sequencing analogous regions in nuclear genes (for exam-
ple, the KRAS codon 12 or the BRAF V599 mutations).
Both of theses caveats have enormous implications in
terms of sensitivity in the context of cancer biomarker
studies, and underscore the importance of complete
mtDNA sequencing.
In our series, we were able to detect at least one somatic
alteration in all preneoplastic samples analyzed, although
there was a wide range (1 – 35) in the number of variants
within a given case. It is important to stress that chip-
based chemistry is best suited for detection of single base
pair alterations [24,31], and it is likely that we are missing
insertions/deletions, frameshift mutations, and large dele-
tions, all of which have been reported in cancer samples.
In addition, because we are not using lymphocyte DNA as
a germline control, there is a potential for underestimat-
ing the true frequency of somatic alterations, since some
mtDNA alterations will be common in both histologically
"normal" tissue and preneoplasia, as a result of a field
defect. Nevertheless, there does not appear to be a signifi-
cant attrition in terms of false negative cases, as we are
able to demonstrate at least one somatic alteration in all
14 of preneoplastic lesions examined, when compared to
the paired histologically normal specimen.
Barrett esophagus is the recognized precursor lesion of
esophageal adenocarcinoma, and the prevalence of this
disease is dramatically increasing in the Caucasian popu-
lation [32]. Patients with Barrett's esophagus have a 30- to
Sessile serrated adenoma with a mitochondrial mutator phenotype Figure 2
Sessile serrated adenoma with a mitochondrial mutator phenotype. (A) Low power and (B) high power demonstrating the ser-
rated architecture of the glands. Hematoxylin and eosin stain.Molecular Cancer 2006, 5:73 http://www.molecular-cancer.com/content/5/1/73
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125-fold increased risk of the development of esophageal
cancer in comparison with the general population. Unfor-
tunately, the cancer usually manifests at an advanced
stage, such that esophageal adenocarcinoma carries a high
mortality rate [33]. The American Cancer Society esti-
mates that there will be about 14,550 new cases of this
cancer in 2006, and about 13,770 people will die of the
disease. Thus, there is an urgent need to develop effective
early detection strategies for Barrett esophagus-associated
adenocarcinomas, prior to the onset of invasive cancer.
Our studies confirm that somatic mtDNA alterations are a
frequent accompaniment of the metaplastic epithelium
characteristic of Barrett esophagus. Of note, we detect
mtDNA alterations even at the earliest histologic stages of
the multistep progression model of esophageal adenocar-
cinoma, namely, in Barrett mucosa without evidence of
dysplasia, and find no significant differences in the overall
frequency of sequence variations between Barrett mucosa
with or without dysplasia. On the contrary, there is a trend
towards higher rate of non-synonymous mutations in
samples with dysplasia (9/23 or 39%) versus those with-
out dysplasia (2/15 or 13%). The significance of this latter
difference is uncertain and will need to be confirmed in
larger series; however, one can speculate that the increased
prevalence of non-synonymous changes, with the poten-
tial effect on mitochondrial protein function, might pro-
vide a selective advantage in the advanced histologic
lesions. The presence of clonal genetic alterations in non-
dysplastic Barrett epithelium is not unexpected; for exam-
ple, we have reported the occurrence of homozygous
chromosome 9p21 deletions, encompassing the
CDKN2A/p16 gene, in 16% of Barrett epithelia even in the
absence of dysplasia [34]. Meltzer and colleagues recently
performed a global expression analysis of Barrett esopha-
gus, normal squamous mucosa and esophageal adenocar-
cinoma, and found that molecular events at the
transcriptional level in Barrett esophagus are remarkably
similar to Barrett-associated adenocarcinoma [35]. There-
fore, despite the "innocuous" histology, Barrett mucosa,
even when non-dysplastic, may be more ominous than
previously considered at a molecular level.
There are two major pathways to colorectal carcinogenesis
– one preceded by the development of adenomas, and the
other in the backdrop of long-standing inflammatory col-
itis, including ulcerative colitis and Crohn's disease
[36,37]. Despite the eventual progression to colorectal
adenocarcinomas, the genetic mechanisms implicated are
quite distinct in the two pathways. For example, the ade-
noma-carcinoma sequence is characterized by nearly
ubiquitous aberrations in the wnt signaling pathway, such
as APC or β-catenin gene mutations [38]. In contrast, coli-
tis-associated dysplasia and carcinomas commonly dem-
onstrate abnormalities of p53 gene function as an early
event [39]. We examined colorectal cancer precursor
lesions from both scenarios (adenomas and IBD dyspla-
sia), and identified mtDNA alterations in all seven speci-
mens. Of note, we detected multiple somatic alterations
that were present in more than 1 adenoma; in particular a
Thr415Ala mutation in the COI  gene (RCRS position
7146) was present in 3 of 4 adenomas. Curiously, this
identical mutation has been previously reported in associ-
ation with Alzheimer disease [40], but we could not deter-
mine a reported association with cancer. Nevertheless, its
occurrence in multiple adenomas suggests a putative
pathogenic role, as well as the potential for its exploita-
tion as a cancer biomarker in clinical samples, both of
which contentions need to be borne out in further studies
using an expanded sample of adenomas. Mutations of the
cytochrome oxidase gene family with corresponding bio-
chemical defects have been reported not only in colorectal
carcinomas, but also in isolated colonic crypts [41,42]. In
fact, it has been hypothesized that these early genetic
lesions may "mark" the colonic crypt cells eventually pro-
gressing to cancer, although their precise contributory role
to neoplastic progression is of course difficult to deter-
mine. The absence of the Thr415Ala mutation, or other
adenoma-associated sequence alterations, in the three col-
itis-associated dysplasia cases also reiterates what is
known from the study of nuclear genes; i.e., the genetic
pathways in the two precursor lesions of colorectal cancer
are distinct. However, one needs to stress the relatively few
numbers of cases in each category, and larger numbers of
cases may cement this contention.
In our series, we also had the opportunity to examine a
sessile serrated adenoma (SSA), which harbored a striking
number (N = 35) of somatic mtDNA alterations, all but
one of which were transition mutations. We were able to
exclude a sample mismatch by identity testing, which may
have been a potential explanation for the sequence dis-
crepancies. Given the established association between
SSAs and nuclear  mismatch repair (MMR) deficiency
[21,43,44], which likely accounts for the increased predis-
position of these lesions to progress to invasive adenocar-
cinomas, we assessed MMR status in the SSA. Based on
absence of the Bethesda criteria for MMR deficiency, we
confirmed that nuclear DNA from the SSA was microsat-
ellite stable. However, MMR is only one of the six major
types of DNA repair existent in the cell, and most path-
ways have distinct nuclear and mitochondrial compo-
nents [45,46]. The underlying basis for the exceptionally
large number of mtDNA alterations in this "mitochon-
drial mutator" adenoma remains unknown, and a larger
series of colorectal adenomas of the serrated and non-ser-
rated subtypes would have to be examined in order to
determine whether our rudimentary observation in a sin-
gle SSA bears out in other specimens of this nature.Molecular Cancer 2006, 5:73 http://www.molecular-cancer.com/content/5/1/73
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In summary, our preliminary study confirms that mtDNA
alterations are highly prevalent in preneoplastic lesions of
the gastrointestinal tract. This is the first study to demon-
strate feasibility of using an array-based approach for
complete mitochondrial sequencing of preneoplastic
lesions, and adds to the cumulative evidence that mtDNA
is a rational biomarker for the early detection of cancer.
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